Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944541
3.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res
; 36(7): 93, 2019 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044267
4.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
5.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655421
6.
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Future Oncol
; 11(1): 51-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-24901734
7.
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
Blood Adv
; 7(4): 602-610, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541957
8.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
J Clin Oncol
; 41(21): 3689-3699, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279408
9.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 114(6): 1166-73, 2009 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19470696
10.
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma
; 61(13): 3188-3197, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32762271
11.
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Lancet Haematol
; 6(7): e366-e374, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31109827
12.
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 19(11): 715-722.e6, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447270
13.
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Breast Cancer Res Treat
; 110(2): 327-35, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17851757
14.
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Mol Cancer Ther
; 6(9): 2458-67, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17876043
15.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Leuk Lymphoma
; 59(9): 2075-2084, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29295653
16.
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 18(10): 648-657.e15, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30061088
17.
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Cancer Med
; 7(4): 1043-1055, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29533000
18.
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
J Clin Oncol
; 21(13): 2492-9, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12829668
19.
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
J Clin Oncol
; 20(4): 1026-35, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11844826
20.
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
Leukemia
; 34(8): 2271-2275, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32071430